
Veracyte reports strong Q2 2026 growth, evolving into a self-funded cancer diagnostic platform.
Veracyte showed 15% revenue growth and 23% adjusted EBITDA growth in Q2 2026, with a 29.2% EBITDA margin and strong cash flow, operating without funded debt. The company is transitioning from a two-product genomic testing firm to a broader self-funde...


